Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
OpenAI Rejects Apple Trade Secret Theft Claims 
OpenAI Nears Astra AI Model Launch With Safety Focus 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
France Targets Shein, Temu With Fast-Fashion Fees 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Add as a preferred source on Google
AUSTIN, Texas, March 19, 2018 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that its management will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, taking place March 20-21 at the Westin New York Grand Central hotel in New York City.
| Presentation Details | ||
| Date: | Wednesday, March 21 | |
| Time: | 10:20am Eastern Time | |
| Location: | Track 3 | |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact:
Andrew McDonald, Ph.D.
[email protected]
646-597-6987
Adam Cutler
Chief Financial Officer
[email protected]
862-204-4006
